18-month efficacy endpoint analysis
SEPARATION
Since the primary analysis at 12 months, the observation at month 18 showed a further separation of the treatment arm vs. sham over the additional 6-month period for both ACP doses. GA lesion growth, square root transformed, was reduced by 28.1% (0.168 mm, 95% CI [0.066, 0.271]) in the ACP 2 mg–treated eyes when compared to sham (least squares mean values of 0.60 and 0.43 mm, respectively). Likewise, GA lesion growth was reduced by 30.0% (0.167 mm, 95% CI [0.062, 0.273]) in ACP 4 mg–treated eyes when compared to sham (least squares mean values of 0.56 and 0.39 mm, respectively) (Fig. 